Elite 50% OFF Act now – get top investing tools Register Now!

Eledon Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Eledon Pharmaceuticals, Inc.

Nov-18	Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine ELDN GlobeNewswire
Nov-14	Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results ELDN GlobeNewswire
Nov-12	Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants ELDN GlobeNewswire
Nov-11	Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants ELDN GlobeNewswire
Nov-06	Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting ELDN GlobeNewswire
Nov-05	Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference ELDN GlobeNewswire
Oct-17	Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting ELDN GlobeNewswire
Sep-24	Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association ELDN GlobeNewswire
Aug-29	Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025 ELDN GlobeNewswire
Aug-14	Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results ELDN GlobeNewswire
Aug-06	Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation ELDN GlobeNewswire
Jul-30	Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025 ELDN GlobeNewswire
Jul-17	Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025 ELDN GlobeNewswire
Jun-25	Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City ELDN GlobeNewswire
May-14	Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results ELDN GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.